Table 2.
Risk factors for decreased time to death before heart transplantation.
| Univariable | Multivariable | |||||
|---|---|---|---|---|---|---|
| Variables | HR | 95% CI | p | HR | 95% CI | p |
| Sex (male) | 1.29 | 0.69–2.43 | 0.43 | |||
| Earlier era (presentation before 2007) | 4.00 | 1.83–8.76 | <0.001 | 4.13 | 1.88–9.06 | <0.001 |
| Age at initial presentation (months) | 1.00 | 1.00–1.01 | 0.49 | |||
| Familial history | 1.32 | 0.31–5.51 | 0.71 | |||
| Genetic disease | 1.82 | 0.44–7.58 | 0.41 | |||
| Neuromuscular disease | 2.39 | 0.33–17.50 | 0.39 | |||
| Post-myocarditis | 1.17 | 0.61–2.23 | 0.64 | |||
| Adriamycin-induced | NA | >0.99 | ||||
| Arrhythmia-mediated | NA | >0.99 | ||||
| Idiopathic | 1.66 | 0.87–3.18 | 0.13 | |||
| LVEF (%, median [IQR]) | 1.00 | 0.97–1.04 | 0.89 | |||
| MR ≥ moderate | 1.09 | 0.46–2.61 | 0.84 | |||
| TR ≥ moderate | 3.69 | 1.11–12.24 | 0.033 | 4.31 | 1.26–14.77 | 0.020 |
| IVIG | 0.74 | 0.36–1.52 | 0.42 | |||
| Steroid pulse therapy | 0.91 | 0.22–3.77 | 0.89 | |||
| CRT | 0.71 | 0.10–5.20 | 0.74 | |||
| ECMO | 0.97 | 0.34–2.74 | 0.95 | |||
HR, hazard ratio; CI, confidence interval; LVEF, left ventricular ejection fraction; MR, mitral regurgitation; TR, tricuspid regurgitation; IVIG, intravenous immunoglobulin; CRT, cardiac resynchronization therapy; ECMO, extracorporeal membrane oxygenation.